查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933329

全球介入性腫瘤市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考慮因素以及未來預測（2026-2034）

Interventional Oncology Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 120 Pages | 商品交期: 請詢問到貨日

價格

介入性腫瘤市場成長因素

由於全球癌症負擔日益加重以及對微創癌症治療的需求不斷增長，全球介入腫瘤市場正經歷穩定成長。預計到2025年，全球介入性腫瘤市場規模將達23.4億美元。 預計該市場將從2026年的25.3億美元成長到2034年的47.7億美元，預測期內（2026-2034年）複合年增長率（CAGR）為8.25%。

北美引領全球介入性腫瘤學市場，2025年佔42.20%的市佔率。這主要歸功於其先進的醫療基礎設施、較高的癌症發生率以及早期採用影像引導微創腫瘤治療方法。

介入性腫瘤學是指利用影像導引的微創技術（例如消融術、栓塞術和放射療法）對癌症進行診斷、治療和安寧療護。這些手術方式越來越受到青睞，優於傳統的開放性手術，有住院時間短、併發症風險低、復健快等優勢。

新冠疫情對市場的影響

由於封鎖限制、癌症治療延遲以及門診就診量減少，介入腫瘤學市場在新冠疫情期間經歷了暫時性下滑。 2020年，許多擇期腫瘤治療被推遲，對手術量產生了負面影響。

然而，隨著限制措施的放寬，2021年癌症診斷和治療的就診量顯著增加，彌補了延期手術造成的損失。因此，市場正在重拾成長勢頭，預計在預測期內將穩定成長。

市場趨勢

放射乳化技術的日益普及

介入性腫瘤學市場最顯著的趨勢之一是放射乳化技術的日益普及。 這種微創技術將放射性微球直接輸送到腫瘤的供血血管中，在最大限度減少對周圍組織損傷的同時，摧毀目標腫瘤。

放射乳化療法最初是為治療肝癌而開發的，目前正在探索將其用於治療大腸直腸癌和神經內分泌腫瘤。北美放射學會於2022年6月發表的一項研究報告稱，接受經動脈放射乳化療法治療轉移性大腸直腸癌的患者平均存活期為15個月，這進一步支持了該療法的臨床應用。

市場成長驅動因素

全球癌症發生率上升

癌症發生率的上升是市場成長的主要驅動因素。根據世界衛生組織（WHO）統計，2020年全球約有2,000萬例新增癌症病例和970萬例癌症相關死亡病例。肝癌、肺癌、乳癌和腎癌等常見癌症持續推動對有效治療方案的需求。

轉向微創手術

由於微創手術 (MIS) 具有許多優勢，包括減輕疼痛、縮短住院時間、加速復健以及降低併發症發生率，患者和醫療服務提供者越來越傾向於選擇微創手術。研究表明，與開放性手術相比，接受微創手術的患者併發症更少，這推動了介入性腫瘤學技術的廣泛應用。

市場限制因子

儘管市場成長潛力巨大，但介入性腫瘤學手術和設備的高昂成本仍然是市場面臨的挑戰。先進的影像系統、栓塞裝置和消融技術都需要大量的資金投入。 此外，訓練有素的介入性腫瘤科醫生短缺，尤其是在發展中地區，限制了市場滲透率和患者獲得先進治療的機會。

市場區隔分析

依類型

預計2026年，放射治療設備將佔市場主導地位，市佔率達49.48%，主要得益於癌症相關住院人數的增加。栓塞設備由於其精準性和有效性，預計將實現最高的複合年增長率。

依癌症類型

預計到2026年，肝癌細分市場將佔最大的市場佔有率，達到59.70%，這主要歸功於栓塞和消融療法的高普及率。

依最終使用者

預計到2026年，醫院將佔市場主導地位，市場佔有率達67.34%，這主要得益於患者數量的增加和先進治療基礎設施的發展。

區域概覽

  • 北美：市場規模在2025年達到9.9億美元。預計到2026年，美國市場規模將達到10億美元。
  • 歐洲：肺癌發生率上升和醫療基礎設施改善推動了市場成長。
  • 亞太地區：由於中國、日本和印度的醫療基礎設施改善以及醫療器材普及率提高，預計亞太地區的複合年增長率將最高。

主要公司

主要公司包括波士頓科學公司、西門子醫療、泰爾茂株式會社、美瑞醫療系統、BD和AngioDynamics。產品創新和獲得監管部門批准仍然是關鍵的成長策略。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家癌症盛行率（2025 年）
  • 主要產業趨勢：併購、業務合作
  • 概述：介入性腫瘤學的技術進步
  • 新冠疫情對市場的影響

第五章 全球介入性腫瘤學市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 放射治療設備
    • 消融設備
      • 微波消融
      • 射頻消融
      • 冷凍消融
      • 其他
    • 栓塞設備
      • 微導管
      • 指南年份
  • 市場分析、洞察與預測：依癌症類型劃分
    • 肺癌
    • 肝癌
    • 腎癌
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院
    • 專科診所
    • 其他
  • 市場分析，洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區 (ROW)

第六章：北美介入性腫瘤市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲介入性腫瘤市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第八章 亞太地區介入腫瘤市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 亞太其他地區

第九章：世界其他地區（ROW）介入腫瘤市場分析：洞察與預測（2021-2034）

第十章：競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • Boston Scientific Corporation
    • Merit Medical Systems
    • Terumo Corporation
    • Siemens Healthcare GmbH
    • BD
    • AngioDynamics
    • Hologic, Inc.
    • Teleflex Incorporated
Product Code: FBI101986

Growth Factors of interventional oncology Market

The global interventional oncology market is experiencing consistent growth due to the rising global cancer burden and increasing preference for minimally invasive cancer treatment procedures. In 2025, the global interventional oncology market was valued at USD 2.34 billion. The market is projected to grow from USD 2.53 billion in 2026 and reach USD 4.77 billion by 2034, registering a CAGR of 8.25% during the forecast period (2026-2034).

North America dominated the global interventional oncology market with a 42.20% market share in 2025, driven by advanced healthcare infrastructure, high cancer prevalence, and early adoption of image-guided minimally invasive oncology procedures.

Interventional oncology involves the diagnosis, treatment, and palliation of cancer using image-guided, minimally invasive techniques, including ablation, embolization, and radiation-based therapies. These procedures offer benefits such as reduced hospital stays, lower complication risks, and faster recovery, making them increasingly preferred over conventional open surgeries.

Impact of COVID-19 on the Market

The interventional oncology market witnessed a temporary decline during the COVID-19 pandemic due to lockdown restrictions, postponed cancer treatments, and reduced hospital visits. Many elective oncology procedures were delayed in 2020, negatively impacting procedural volumes.

However, with the lifting of restrictions, hospital visits for cancer diagnosis and treatment increased significantly in 2021, compensating for the delayed procedures. As a result, the market regained momentum and is expected to witness steady growth throughout the forecast period.

Market Trends

Growing Adoption of Radioembolization

One of the most prominent trends in the interventional oncology market is the increasing adoption of radioembolization. This minimally invasive technique delivers radioactive microspheres directly to tumor-feeding blood vessels, offering targeted tumor destruction with minimal damage to surrounding tissues.

Originally developed for liver cancer, radioembolization is now being explored for colorectal cancer and neuroendocrine tumors. In June 2022, research published by the Radiological Society of North America reported a 15-month survival rate in patients undergoing transarterial radioembolization for metastatic colorectal cancer, further supporting its clinical adoption.

Market Growth Drivers

Rising Global Cancer Prevalence

The increasing prevalence of cancer is a major driver of market growth. According to the World Health Organization (WHO), there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2020. Common cancers such as liver, lung, breast, and kidney cancers continue to drive demand for effective treatment solutions.

Shift Toward Minimally Invasive Procedures

Patients and healthcare providers are increasingly preferring minimally invasive surgical (MIS) procedures due to advantages such as reduced pain, shorter hospital stays, faster recovery, and lower complication rates. Studies have shown that patients undergoing MIS procedures experience fewer complications compared to open surgery, encouraging wider adoption of interventional oncology techniques.

Market Restraints

Despite strong growth potential, the market faces challenges related to the high cost of interventional oncology procedures and devices. Advanced imaging systems, embolization devices, and ablation technologies require significant capital investment. Additionally, the shortage of trained interventional oncologists, especially in developing regions, limits market penetration and patient access to advanced treatments.

Segmentation Analysis

By Type

Radiation therapy devices dominated the market with a 49.48% share in 2026, supported by rising cancer-related hospitalizations. Embolization devices are expected to register the highest CAGR due to their precision and effectiveness.

By Cancer Type

The liver cancer segment held the largest market share at 59.70% in 2026, driven by high adoption of embolization and ablation therapies.

By End User

Hospitals dominated the market with a 67.34% share in 2026, owing to increasing patient admissions and availability of advanced treatment infrastructure.

Regional Insights

  • North America: Market value reached USD 0.99 billion in 2025; the U.S. market is projected to reach USD 1.0 billion by 2026.
  • Europe: Growth supported by rising lung cancer prevalence and improved healthcare infrastructure.
  • Asia Pacific: Expected to grow at the highest CAGR due to infrastructure development and increasing device launches in China, Japan, and India.

Key Industry Players

Major companies include Boston Scientific Corporation, Siemens Healthineers, Terumo Corporation, Merit Medical Systems, BD, and AngioDynamics. Product innovation and regulatory approvals remain key growth strategies.

Conclusion

The global interventional oncology market is set to witness robust growth, expanding from USD 2.34 billion in 2025 to USD 4.77 billion by 2034. Rising cancer prevalence, growing preference for minimally invasive procedures, and continuous technological advancements are driving market expansion. Although high treatment costs and limited availability of skilled professionals pose challenges, increasing investments in healthcare infrastructure and innovation are expected to support sustained market growth during the forecast period.

Segmentation By Type

  • Radiation Therapy Devices
  • Ablation Devices
    • Microwave ablation
    • Radiofrequency ablation
    • Cryoablation
    • Others
  • Embolization Devices
    • Microcatheters
    • Guidewires

By Cancer Type

  • Lung Cancer
  • Liver Cancer
  • Kidney Cancer
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (By Type, Cancer Type, End-user, and Country)
    • U.S. (By Cancer Type)
    • Canada (By Cancer Type)
  • Europe (By Type, Cancer Type, End-user, and Country/Sub-region)
    • U.K. (By Cancer Type)
    • Germany (By Cancer Type)
    • France (By Cancer Type)
    • Spain (By Cancer Type)
    • Italy (By Cancer Type)
    • Rest of Europe (By Cancer Type)
  • Asia Pacific (By Type, Cancer Type, End-user, and Country/Sub-region)
    • Japan (By Cancer Type)
    • China (By Cancer Type)
    • India (By Cancer Type)
    • Australia (By Cancer Type)
    • Rest of Asia Pacific (By Cancer Type)
  • Rest of the World (By Type, Cancer Type, and End-user)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer Diseases, By Key Countries, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships)
  • 4.3. Overview: Technological Advancements in Interventional Oncology
  • 4.4. Impact of COVID-19 on the Market

5. Global Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Radiation Therapy Devices
    • 5.1.2. Ablation Devices
      • 5.1.2.1. Microwave Ablation
      • 5.1.2.2. Radiofrequency Ablation
      • 5.1.2.3. Cryoablation
      • 5.1.2.4. Others
    • 5.1.3. Embolization Devices
      • 5.1.3.1. Microcatheters
      • 5.1.3.2. Guidewires
  • 5.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.2.1. Lung Cancer
    • 5.2.2. Liver Cancer
    • 5.2.3. Kidney Cancer
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals
    • 5.3.2. Specialty Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Radiation Therapy Devices
    • 6.1.2. Ablation Devices
      • 6.1.2.1. Microwave Ablation
      • 6.1.2.2. Radiofrequency Ablation
      • 6.1.2.3. Cryoablation
      • 6.1.2.4. Others
    • 6.1.3. Embolization Devices
      • 6.1.3.1. Microcatheters
      • 6.1.3.2. Guidewires
  • 6.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.2.1. Lung Cancer
    • 6.2.2. Liver Cancer
    • 6.2.3. Kidney Cancer
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals
    • 6.3.2. Specialty Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Cancer Type
    • 6.4.2. Canada
      • 6.4.2.1. By Cancer Type

7. Europe Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Radiation Therapy Devices
    • 7.1.2. Ablation Devices
      • 7.1.2.1. Microwave Ablation
      • 7.1.2.2. Radiofrequency Ablation
      • 7.1.2.3. Cryoablation
      • 7.1.2.4. Others
    • 7.1.3. Embolization Devices
      • 7.1.3.1. Microcatheters
      • 7.1.3.2. Guidewires
  • 7.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.2.1. Lung Cancer
    • 7.2.2. Liver Cancer
    • 7.2.3. Kidney Cancer
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
      • 7.4.1.1. By Cancer Type
    • 7.4.2. Germany
      • 7.4.2.1. By Cancer Type
    • 7.4.3. France
      • 7.4.3.1. By Cancer Type
    • 7.4.4. Spain
      • 7.4.4.1. By Cancer Type
    • 7.4.5. Italy
      • 7.4.5.1. By Cancer Type
    • 7.4.6. Rest of Europe
      • 7.4.6.1. By Cancer Type

8. Asia Pacific Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Radiation Therapy Devices
    • 8.1.2. Ablation Devices
      • 8.1.2.1. Microwave Ablation
      • 8.1.2.2. Radiofrequency Ablation
      • 8.1.2.3. Cryoablation
      • 8.1.2.4. Others
    • 8.1.3. Embolization Devices
      • 8.1.3.1. Microcatheters
      • 8.1.3.2. Guidewires
  • 8.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.2.1. Lung Cancer
    • 8.2.2. Liver Cancer
    • 8.2.3. Kidney Cancer
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals
    • 8.3.2. Specialty Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Cancer Type
    • 8.4.2. China
      • 8.4.2.1. By Cancer Type
    • 8.4.3. India
      • 8.4.3.1. By Cancer Type
    • 8.4.4. Australia
      • 8.4.4.1. By Cancer Type
    • 8.4.5. Rest of Asia Pacific
      • 8.4.5.1. By Cancer Type

9. Rest of the World Interventional Oncology Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Radiation Therapy Devices
    • 9.1.2. Ablation Devices
      • 9.1.2.1. Microwave Ablation
      • 9.1.2.2. Radiofrequency Ablation
      • 9.1.2.3. Cryoablation
      • 9.1.2.4. Others
    • 9.1.3. Embolization Devices
      • 9.1.3.1. Microcatheters
      • 9.1.3.2. Guidewires
  • 9.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.2.1. Lung Cancer
    • 9.2.2. Liver Cancer
    • 9.2.3. Kidney Cancer
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Boston Scientific Corporation
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Merit Medical Systems
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Terumo Corporation
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Siemens Healthcare GmbH
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. BD
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. AngioDynamics
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Hologic, Inc.
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Teleflex Incorporated
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 3: Global Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 4: Global Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 5: Global Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 6: Global Interventional Oncology Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 9: North America Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 10: North America Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 11: North America Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 12: North America Interventional Oncology Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: U.S. Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 14: Canada Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 15: Europe Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 17: Europe Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 18: Europe Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 19: Europe Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 20: Europe Interventional Oncology Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: U.K. Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 22: Germany Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 23: France Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 24: Spain Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 25: Italy Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 26: Rest of the Europe Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 27: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 28: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 29: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 30: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 31: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 32: Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 33: China Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 34: Japan Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 35: India Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 36: Australia Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 37: Rest of the Asia Pacific Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 38: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 39: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, Ablation Devices, 2021-2034
  • Table 40: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, Embolization Devices, 2021-2034
  • Table 41: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, By Cancer Type, 2021-2034
  • Table 42: Rest of the World Interventional Oncology Market Revenue (USD billion) Forecast, by End-user, 2021-2034

List of Figures

  • Figure 1: Global Interventional Oncology Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Interventional Oncology Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Interventional Oncology Market Value Share (%), By Cancer Type, 2025 & 2034
  • Figure 4: Global Interventional Oncology Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Interventional Oncology Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 8: North America Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 9: North America Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 10: North America Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 12: North America Interventional Oncology Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Interventional Oncology Market Value Share (%), By Country, 2025
  • Figure 14: Europe Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 16: Europe Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 17: Europe Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 18: Europe Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Interventional Oncology Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Interventional Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 25: Asia Pacific Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 26: Asia Pacific Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Interventional Oncology Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Interventional Oncology Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World Interventional Oncology Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Rest of the World Interventional Oncology Market Value Share (%), by Type, 2025
  • Figure 32: Rest of the World Interventional Oncology Market Value (USD billion), By Cancer Type, 2025 & 2034
  • Figure 33: Rest of the World Interventional Oncology Market Value Share (%), By Cancer Type, 2025
  • Figure 34: Rest of the World Interventional Oncology Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Rest of the World Interventional Oncology Market Value Share (%), by End-user, 2025
  • Figure 36: Global Interventional Oncology Market Share (%), By Company, 2025